The Prionlike Domain of FUS is Multiphosphorylated Following DNA Damage Without Altering Nuclear Localization

Overview

Journal Mol Biol Cell

Specialties Cell Biology
Molecular Biology

Date 2018 Jun 14

PMID 29897835

Citations 30

Authors

Shannon N Rhoads

Zachary T Monahan

Debra S Yee

Andrew Y Leung

Cameron G Newcombe

Robert N OMeally

Robert N Cole

Frank P Shewmaker

Affiliations

Soon will be listed here.

Abstract

FUS (fused in sarcoma) is an abundant, predominantly nuclear protein involved in RNA processing. Under various conditions, FUS functionally associates with RNA and other macromolecules to form distinct, reversible phase-separated liquid structures. Persistence of the phase-separated state and increased cytoplasmic localization are both hypothesized to predispose FUS to irreversible aggregation, which is a pathological hallmark of subtypes of amyotrophic lateral sclerosis and frontotemporal dementia. We previously showed that phosphorylation of FUS's prionlike domain suppressed phase separation and toxic aggregation, proportionally to the number of added phosphates. However, phosphorylation of FUS's prionlike domain was previously reported to promote its cytoplasmic localization, potentially favoring pathological behavior. Here we used mass spectrometry and human cell models to further identify phosphorylation sites within FUS's prionlike domain, specifically following DNA-damaging stress. In total, 28 putative sites have been identified, about half of which are DNA-dependent protein kinase (DNA-PK) consensus sites. Custom antibodies were developed to confirm the phosphorylation of two of these sites (Ser-26 and Ser-30). Both sites were usually phosphorylated in a subpopulation of cellular FUS following a variety of DNA-damaging stresses but not necessarily equally or simultaneously. Importantly, we found DNA-PK-dependent multiphosphorylation of FUS's prionlike domain does not cause cytoplasmic localization.

Citing Articles

Biomolecular condensates and disease pathogenesis.

Ruan K, Bai G, Fang Y, Li D, Li T, Liu X Sci China Life Sci. 2024; 67(9):1792-1832.

PMID: 39037698 DOI: 10.1007/s11427-024-2661-3.

FUS unveiled in mitochondrial DNA repair and targeted ligase-1 expression rescues repair-defects in FUS-linked motor neuron disease.

Kodavati M, Wang H, Guo W, Mitra J, Hegde P, Provasek V Nat Commun. 2024; 15(1):2156.

PMID: 38461154 PMC: 10925063. DOI: 10.1038/s41467-024-45978-6.

Crosstalk between protein post-translational modifications and phase separation.

Liu Y, Feng W, Wang Y, Wu B Cell Commun Signal. 2024; 22(1):110.

PMID: 38347544 PMC: 10860296. DOI: 10.1186/s12964-023-01380-1.

A chaperone-like function of FUS ensures TAZ condensate dynamics and transcriptional activation.

Shao Y, Shu X, Lu Y, Zhu W, Li R, Fu H Nat Cell Biol. 2024; 26(1):86-99.

PMID: 38172614 DOI: 10.1038/s41556-023-01309-3.

Small molecules targeting different cellular pathologies for the treatment of amyotrophic lateral sclerosis.

Elmansy M, Reidl C, Rahaman M, Ozdinler P, Silverman R Med Res Rev. 2023; 43(6):2260-2302.

PMID: 37243319 PMC: 10592673. DOI: 10.1002/med.21974.

References

Murakami T, Qamar S, Lin J, Kaminski Schierle G, Rees E, Miyashita A . ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function. Neuron. 2015; 88(4):678-90. PMC: 4660210. DOI: 10.1016/j.neuron.2015.10.030. View

Gitler A, Shorter J . RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion. 2011; 5(3):179-87. PMC: 3226045. DOI: 10.4161/pri.5.3.17230. View

Lin Y, Currie S, Rosen M . Intrinsically disordered sequences enable modulation of protein phase separation through distributed tyrosine motifs. J Biol Chem. 2017; 292(46):19110-19120. PMC: 5704491. DOI: 10.1074/jbc.M117.800466. View

Sun S, Ling S, Qiu J, Albuquerque C, Zhou Y, Tokunaga S . ALS-causative mutations in FUS/TLS confer gain and loss of function by altered association with SMN and U1-snRNP. Nat Commun. 2015; 6:6171. PMC: 4338613. DOI: 10.1038/ncomms7171. View

Tradewell M, Yu Z, Tibshirani M, Boulanger M, Durham H, Richard S . Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum Mol Genet. 2011; 21(1):136-49. DOI: 10.1093/hmg/ddr448. View

Hoell J, Larsson E, Runge S, Nusbaum J, Duggimpudi S, Farazi T . RNA targets of wild-type and mutant FET family proteins. Nat Struct Mol Biol. 2011; 18(12):1428-31. PMC: 3230689. DOI: 10.1038/nsmb.2163. View

Darovic S, Prpar Mihevc S, Zupunski V, Guncar G, Stalekar M, Lee Y . Phosphorylation of C-terminal tyrosine residue 526 in FUS impairs its nuclear import. J Cell Sci. 2015; 128(22):4151-9. DOI: 10.1242/jcs.176602. View

Fujii R, Takumi T . TLS facilitates transport of mRNA encoding an actin-stabilizing protein to dendritic spines. J Cell Sci. 2005; 118(Pt 24):5755-65. DOI: 10.1242/jcs.02692. View

Schwartz J, Podell E, Han S, Berry J, Eggan K, Cech T . FUS is sequestered in nuclear aggregates in ALS patient fibroblasts. Mol Biol Cell. 2014; 25(17):2571-8. PMC: 4148247. DOI: 10.1091/mbc.E14-05-1007. View

10.

Kino Y, Washizu C, Aquilanti E, Okuno M, Kurosawa M, Yamada M . Intracellular localization and splicing regulation of FUS/TLS are variably affected by amyotrophic lateral sclerosis-linked mutations. Nucleic Acids Res. 2010; 39(7):2781-98. PMC: 3074126. DOI: 10.1093/nar/gkq1162. View

11.

Ishihara H, Martin B, Brautigan D, Karaki H, Ozaki H, Kato Y . Calyculin A and okadaic acid: inhibitors of protein phosphatase activity. Biochem Biophys Res Commun. 1989; 159(3):871-7. DOI: 10.1016/0006-291x(89)92189-x. View

12.

Gardiner M, Toth R, Vandermoere F, Morrice N, Rouse J . Identification and characterization of FUS/TLS as a new target of ATM. Biochem J. 2008; 415(2):297-307. DOI: 10.1042/BJ20081135. View

13.

Scaramuzzino C, Monaghan J, Milioto C, Lanson Jr N, Maltare A, Aggarwal T . Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo. PLoS One. 2013; 8(4):e61576. PMC: 3631215. DOI: 10.1371/journal.pone.0061576. View

14.

Daigle J, Lanson Jr N, Smith R, Casci I, Maltare A, Monaghan J . RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet. 2012; 22(6):1193-205. PMC: 3578413. DOI: 10.1093/hmg/dds526. View

15.

Rappsilber J, Friesen W, Paushkin S, Dreyfuss G, Mann M . Detection of arginine dimethylated peptides by parallel precursor ion scanning mass spectrometry in positive ion mode. Anal Chem. 2003; 75(13):3107-14. DOI: 10.1021/ac026283q. View

16.

Karaman M, Herrgard S, Treiber D, Gallant P, Atteridge C, Campbell B . A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008; 26(1):127-32. DOI: 10.1038/nbt1358. View

17.

Neumann M, Rademakers R, Roeber S, Baker M, Kretzschmar H, Mackenzie I . A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009; 132(Pt 11):2922-31. PMC: 2768659. DOI: 10.1093/brain/awp214. View

18.

Kryndushkin D, Wickner R, Shewmaker F . FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis. Protein Cell. 2011; 2(3):223-36. PMC: 4875312. DOI: 10.1007/s13238-011-1525-0. View

19.

Povirk L . DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat Res. 1996; 355(1-2):71-89. DOI: 10.1016/0027-5107(96)00023-1. View

20.

Blackford A, Jackson S . ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Mol Cell. 2017; 66(6):801-817. DOI: 10.1016/j.molcel.2017.05.015. View